Cytotoxic cationic peptides as а ligands for receptor nucleolin
https://doi.org/10.17650/2313-805X-2018-5-3-59-64
Abstract
Background. Chaperone proteins nucleolin (NCL, or C23) and nucleophosmin (NPM, or B23) regulate key cell functions. The most tumors are characterized by over-expression of these proteins, especially in cell nuclei and on the сell surface, as NCL. Differential expression of NCL/NPM in tumor and normal cells is the basis of selective cytotoxicity of cationic peptides – expected ligands for these proteins. Objective. Analysis of the interactions between nucleolin and some peptides with high nonspecific toxicity for tumor cells. Materials and methods. The interaction of 4 previously characterized cationic peptides with nucleolin dimer was analyzed by pair molecular docking using Maestro 11 program. Results and conclusion. It is shown that these peptides can associate with receptor nucleolin molecules, forming energy-stable complexes. In the active centre of NCL molecule were found, at least, 7 positions of amino acids, which bind to the tested peptides at a high frequency (43–100 %). This indicates the conservative structure of dimer NCL, its stable binding to peptide ligands and the possibility of design the optimal structure of cationic peptides that induce tumor cell death due to competing binding to the target proteins.
About the Authors
A. A. LushnikovaRussian Federation
A. V. Kostarev
Russian Federation
D. A. Ponkratova
Russian Federation
A. V. Onyan
Russian Federation
E. G. Glubokova
Russian Federation
S. M. Andreev
Russian Federation
References
1. Fujiki H., Watanabe T., Suganuma M. Cell-sufaсe nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J Cancer Res Clin Oncol 2014;140(7):689–99. DOI: 10.1007/s00432-014-1587-5. PMID: 24469254.
2. Koutsioumpa M., Papadimitriou E. Cellsuface nucleolin as a target for anti-cancer therapies. Recent Part Anticancer Drug Discov 2018;9(2):137–52. PMID: 24251811.
3. Lushnikova A., Ponkratova D., Andreev S. et al. A рossibility for therapy of metastatic cutaneous melanoma with cationic peptides. Eur J Cancer 2017;72(Sl): 127–28.
4. Lushnikova A.A., Ponkratova D.A., Rudakova A.A. et al. The mechanisms of antitumor toxicity in a number of cationic peptides. Modern Science 2017;11:124–6.
5. Lushnikova A.A., Ponkratova D.A., Morozova L.F., Andreev S.M. Induction of apoptosis in cutaneous melanoma cells by cationic peptides. Int Sci J 2017;7– 2(61):75–9.
6. Dang W., Muto Y., Inoue Y. et al. RCSB PDB TI Solution structure of the RRM_1domain of NCL protein. FAUCRDT 2005;12(12). Available at: http://www.rcsb.org/structure/2FC8.
7. Kellenberger E., Rodrigo J., Muller P., Rognan D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004;57(2):225–42. DOI: 10.1002/prot. 20149. PMID: 15340911.
8. Site Map User Manual. Schrödinger: LLC. Schrödinger Press, 2009.
9. Glide User Manual. Schrödinger: LLC. Schrödinger Press, 2015.
10. Induced Fit Docking. Schrödinger: LLC. Schrödinger Press, 2009.
11. Du X., Li Y., Xia Y.L. et al. Insights into protein-ligand interactions: mechanisms, models, and methods. Int J Mol Sci 2016;17(2):144–78. DOI: 10.3390/ijms17020144. PMID: 26821017.
12. Balça-Silva J., do Carmo A., Täo H. et al. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity. Exp Cell Res 2018;370(1): 68–77. DOI: 10.1016/j.yexcr.2018.06.005. PMID: 29902537.
Review
For citations:
Lushnikova A.A., Kostarev A.V., Ponkratova D.A., Onyan A.V., Glubokova E.G., Andreev S.M. Cytotoxic cationic peptides as а ligands for receptor nucleolin. Advances in Molecular Oncology. 2018;5(3):59-64. (In Russ.) https://doi.org/10.17650/2313-805X-2018-5-3-59-64